242 related articles for article (PubMed ID: 33380865)
21. Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients.
Césaire M; Rambeau A; Clatot F; Johnson A; Heutte N; Thariat J
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2453-2461. PubMed ID: 36564669
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
Kokkali S; Ntokou A; Drizou M; Perdikari K; Makaronis P; Katsarou E; Koufopoulos N; Tzovaras A; Ardavanis A
Oral Oncol; 2020 Feb; 101():104359. PubMed ID: 31300270
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
25. Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma.
Tang E; Lahmi L; Meillan N; Pietta G; Albert S; Maingon P
Curr Oncol Rep; 2019 Nov; 21(11):102. PubMed ID: 31728650
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
27. Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression.
Denaro N; Merlano MC
Head Neck; 2019 Mar; 41(3):E42-E47. PubMed ID: 30614126
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
[TBL] [Abstract][Full Text] [Related]
30. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
31. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
32. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
33. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
[TBL] [Abstract][Full Text] [Related]
34. Site of distant metastasis affects the prognosis with recurrent/metastatic head and neck squamous cell carcinoma patients treated with Nivolumab.
Hoshi Y; Shirakura S; Yamada M; Sugiyama T; Koide N; Tamii S; Kamata K; Yokomura M; Osaki S; Ohno T; Yagihara K; Hara H; Beppu T
Int J Clin Oncol; 2023 Sep; 28(9):1139-1146. PubMed ID: 37421478
[TBL] [Abstract][Full Text] [Related]
35. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
36. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
Okamoto I; Tsukahara K; Sato H
Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
[TBL] [Abstract][Full Text] [Related]
37. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
40. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]